Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Sustained stable disease and immune response observed in a patient with metastatic uveal melanoma receiving tebentafusp: a case study

  • By

  • Parham Habibzadeh

  • Anushri Kulkarni

  • Drew Hurd

  • Amy Rose

  • Danielle Bednarz

  • Yana G. Najjar

  • John M. Kirkwood

  • Arivarasan Karunamurthy

  • Diwakar Davar

  • July 2, 2026

Share

Original Source(s)

Durable stable disease and immune activation in metastatic uveal melanoma treated with tebentafusp: case report

  • by Parham Habibzadeh, Anushri Kulkarni, Drew Hurd, Amy Rose, Danielle Bednarz, Yana G. Najjar, John M. Kirkwood, Arivarasan Karunamurthy, Diwakar Davar

  • July 2, 2026

Related Content

The CpG island methylator phenotype defines an immune-cold and therapy-resistant subtype of cutaneous melanoma

An integrative naturopathic oncology approach in metastatic malignant melanoma: two case reports

Comparing the i31-SLNB and the MIA Nomogram for Sentinel Lymph Node Biopsy Positivity Prediction in Cutaneous Melanoma: A Prospective Cohort Analysis